HLA Health HourMedicaid & MedicareInsuranceMental HealthNutritionFind a ProviderHealth JobsProvider Corner
Healthcare Markets
UNH 340.01 ▼0.02%ELV 403.00 ▲1.93%CI 275.00 ▲1.29%CVS 80.97 ▲0.11%HUM 385.25 ▼1.25%CNC 63.94 ▲0.24%MOH 198.50 ▲0.00%HCA 475.00 ▼0.22%THC 263.00 ▼0.07%UHS 179.43 ▼0.12%LLY 1347.00 ▼0.13%PFE 27.40 ▼0.11%JNJ 270.93 ▲0.09%MRK 134.43 ▲0.48%ABBV 286.50 ▼0.35%NVO 37.84 ▲0.08%MDT 99.52 ▼0.55%ABT 104.33 ▲0.99%ISRG 400.17 ▲0.28%XLV 176.86 ▼0.28%Delayed quotes. Not investment advice.UNH 340.01 ▼0.02%ELV 403.00 ▲1.93%CI 275.00 ▲1.29%CVS 80.97 ▲0.11%HUM 385.25 ▼1.25%CNC 63.94 ▲0.24%MOH 198.50 ▲0.00%HCA 475.00 ▼0.22%THC 263.00 ▼0.07%UHS 179.43 ▼0.12%LLY 1347.00 ▼0.13%PFE 27.40 ▼0.11%JNJ 270.93 ▲0.09%MRK 134.43 ▲0.48%ABBV 286.50 ▼0.35%NVO 37.84 ▲0.08%MDT 99.52 ▼0.55%ABT 104.33 ▲0.99%ISRG 400.17 ▲0.28%XLV 176.86 ▼0.28%Delayed quotes. Not investment advice.
Saturday, November 21, 2026
Edition
HELPMORNING BRIEFING
HLA Network News
HealthLink of America
HEALTHLINK OF AMERICA NEWS / RESOURCES
NORTH CAROLINA HEALTH PLANS
NC MedicaidMedicareBlue Cross NCHealthy BlueAmeriHealth Caritas NCCarolina Complete HealthUnitedHealthcare Community PlanWellCare of NCAlliance HealthTrillium Health ResourcesVaya PartnersAetnaHumanaCigna
All plans ›
ADVERTISEMENT
ADVERTISE WITH HLA NETWORK NEWS
Reach patients, families and providers in their city.
Health brands only. Banner, sidebar, section, directory, jobs and Morning Briefing placements.
GET THE MEDIA KIT
Providers & Industry · national

Experimental drug shows promise against hard-to-treat lung and pancreatic cancers

Early trial results suggest ERAS-0015 shrinks tumors in patients with RAS gene mutations.

An experimental cancer drug called ERAS-0015 has shown it is safe and can shrink tumors in patients with lung and pancreatic cancer, according to early trial results presented at a medical symposium in Barcelona. The drug targets cancers driven by mutations in the RAS gene, which were previously thought impossible to treat with medication.

The AURORAS-1 Phase I trial involved 148 patients who had already tried other cancer treatments. According to the European Organisation for Research and Treatment of Cancer, ERAS-0015 caused tumors to shrink significantly in 44% of patients with RAS-mutant pancreatic cancer and 60% of patients with RAS-mutant lung cancer.

The drug works as a "pan-RAS molecular glue," meaning it brings proteins together in a way that blocks growth signals from several different RAS mutations. RAS mutations act like switches stuck in the "on" position, continuously sending signals that fuel cancer. ERAS-0015 is designed to bind to these switches and stop those signals.

Medical oncologist Dr. Judy Wang told the symposium that ERAS-0015 was well tolerated with few severe side effects. The results are significant because patients with RAS-mutant cancers have had few or no treatment options available.

What it means in Raleigh

RALEIGH HEALTH SYSTEM
State agency: NC Department of Health and Human Services (NCDHHS)
Behavioral health: Alliance Health (LME/MCO for Wake, Durham, Johnston, Orange, Cumberland, Mecklenburg)
Medicaid plans: NC Medicaid Standard Plans: AmeriHealth Caritas NC, Carolina Complete Health, Healthy Blue, UnitedHealthcare Community Plan, WellCare of NC. Tailored Plans: Alliance Health, Trillium Health Resources, Vaya Partners (Vaya Health + Partners Health Management, merged 2026).
Major insurers: Blue Cross NC, Aetna, Cigna, UnitedHealthcare, Humana
Plan lists change; confirm with your plan or the state agency.

Sources

Not medical advice. HLA Network News reports health news. Talk to your doctor or care team about your own care. In a crisis, call or text 988. In an emergency, call 911.
ADVERTISEMENT · SIDEBAR 300x250
Reach health readers here. Advertise with HLA